USA - NASDAQ:DARE - US23666P2002 - Common Stock
We assign a fundamental rating of 3 out of 10 to DARE. DARE was compared to 192 industry peers in the Pharmaceuticals industry. DARE has a bad profitability rating. Also its financial health evaluation is rather negative. DARE has a valuation in line with the averages, but it does not seem to be growing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9% | ||
| ROE | N/A | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 108.6% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 1.2 | ||
| Altman-Z | -17.43 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.56 | ||
| Quick Ratio | 0.56 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.96 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.55 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:DARE (10/28/2025, 8:00:01 PM)
2.03
0 (0%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.96 | ||
| P/S | 305.75 | ||
| P/FCF | 4.55 | ||
| P/OCF | 4.06 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 108.6% | ||
| FCFM | 6719.11% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 1.2 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 381.33% | ||
| Cap/Sales | 807.82% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.56 | ||
| Quick Ratio | 0.56 | ||
| Altman-Z | -17.43 |
ChartMill assigns a fundamental rating of 3 / 10 to DARE.
ChartMill assigns a valuation rating of 5 / 10 to DARE BIOSCIENCE INC (DARE). This can be considered as Fairly Valued.
DARE BIOSCIENCE INC (DARE) has a profitability rating of 2 / 10.
The Earnings per Share (EPS) of DARE BIOSCIENCE INC (DARE) is expected to decline by -204.04% in the next year.